Precocious adrenarche in children under five years old with adrenal adenocarcinoma
DOI:
https://doi.org/10.18554/refacs.v14i00.8482Keywords:
Adrenal gland neoplasms, Adrenal gland diseases, Adrenocortical carcinomaAbstract
Objective: describe the main laboratory, imaging and histopathological findings in pediatric patients with adrenal adenocarcinoma, as well as the clinical progression of the analyzed cases. Methods: descriptive study was conducted by reviewing medical records of children seen at the Endocrinology and Metabolism Department from a tertiary hospital in the Brazil, from October 1999 to March 2024. Results: four cases with ages at diagnosis ranging from six months to two years and six months, female and with precocious adrenarche. During the follow-up, only one patient developed recurrent metastases and subsequently died. Three have shown good progress to date. Conclusion: early diagnosis and active postoperative surveillance are crucial for a favorable prognosis and survival of patients with adrenal adenocarcinoma.
References
1. Bachega FS, Suartz CV, Almeida MQ, Brondani VB, Charchar HLS, Lacombe AMF, et al. Retrospective analysis of prognostic factors in pediatric patients with adrenocortical tumor from unique tertiary center with long-term follow-up. J Clin Med. [Internet]. 2022 [citado em 12 out 2024]; 11(22):6641. DOI: https://doi.org/10.3390/jcm11226641
2. Kumar S, Tiwari P, Das RK, Kundu AK. Virilizing adrenal carcinoma in a 3-year-old boy: a rarity. Indian J Med Paediatr Oncol. [Internet]. 2010 [citado em 12 maio 2024]; 31(1):30-2. DOI: https://doi.org/10.4103/0971-5851.68851
3. Antonini SR, Leal LF, Cavalcanti MM. Pediatric adrenocortical tumors: diagnosis, management and advancements in the understanding of the genetic basis and therapeutic implications. Expert Rev Endocrinol Metab. [Internet]. 2014 [citado em 12 jul 2024]; 9(5):445-64. DOI: https://doi.org/10.1586/17446651.2014.941813
4. Zambaiti E, Duci M, De Corti F, Gamba P, Dall'Igna P, Ghidini F, et al. Clinical prognostic factors in pediatric adrenocortical tumors: a meta-analysis. Pediatr Blood Cancer [Internet]. 2021 [citado em 12 jun 2024]; 68(3):e28836. DOI: https://doi.org/10.1002/pbc.28836
5. Almeida MQ, Bezerra-Neto JE, Mendonça BB, Latronico AC, Fragoso MCBV. Primary malignant tumors of the adrenal glands. Clinics (Sao Paulo) [Internet]. 2018 [citado em 12 jul 2024]; 73(Suppl 1):e756s. DOI: https://doi.org/10.6061/clinics/2018/e756s
6. Monteiro NML, Rodrigues KES, Vidigal PVT, Oliveira BM. Adrenal carcinoma in children: longitudinal study in Minas Gerais, Brazil. Rev Paul Pediatr. [Internet]. 2019 [citado em 12 jun 2024]; 37(1):20-6. DOI: https://doi.org/10.1590/1984-0462/;2019;37;1;00002
7. Srougi V, Bancos I, Daher M, Lee JE, Graham PH, Karam JA, et al. Cytoreductive surgery of the primary tumor in metastatic adrenocortical carcinoma: impact on patients' survival. J Clin Endocrinol Metab. [Internet]. 2022 [citado em 12 out 2024]; 107(4):964-71. DOI: https://doi.org/10.1210/clinem/dgab865
8. Fassnacht M, Libé R, Kroiss M, Allolio B. Adrenocortical carcinoma: a clinician's update. Nat Rev Endocrinol. [Internet]. 2011 [citado em 12 out 2024]; 7(6):323-35. DOI: https://doi.org/10.1038/nrendo.2010.235
9. Fassnacht M, Tsagarakis S, Terzolo M, Tabarin A, Sahdev A, Newell-Price J, et al. European Society of Endocrinology clinical practice guidelines on the management of adrenal incidentalomas, in collaboration with the European Network for the Study of Adrenal Tumors. Eur J Endocrinol. [Internet]. 2023 [citado em 12 out 2024]; 189(1):G1-G42. DOI: https://doi.org/10.1093/ejendo/lvad066
10. Weiss LM. Comparative histologic study of 43 metastasizing and nonmetastasizing adrenocortical tumors. Am J Surg Pathol. [Internet]. 1984 [citado em 14 jun 2024]; 8(3):163-9. DOI: https://doi.org/10.1097/00000478-198403000-00001
11. Fassnacht M, Johanssen S, Quinkler M, Bucsky P, Willenberg HS, Beuschlein F, et al. Limited prognostic value of the 2004 International Union Against Cancer staging classification for adrenocortical carcinoma: proposal for a Revised TNM Classification. Cancer [Internet]. 2009 [citado em 23 jun 2024]; 115(2):243-50. DOI: https://doi.org/10.1002/cncr.24030
12. Lin W, Dai J, Xie J, Liu J, Sun F, Huang X, et al. S-GRAS score performs better than a model from SEER for patients with adrenocortical carcinoma. Endocr Connect. [Internet]. 2022 [citado em 12 jun 2024]; 11(6):e220114. DOI: https://doi.org/10.1530/EC-22-0114
13. Elhassan YS, Altieri B, Berhane S, Cosentini D, Calabrese A, Haissaguerre M, et al. S-GRAS score for prognostic classification of adrenocortical carcinoma: an international, multicenter ENSAT study. Eur J Endocrinol. [Internet]. 2021 [citado em 12 jun 2024]; 186(1):25-36. DOI: https://doi.org/10.1530/EJE-21-0510
14. Riedmeier M, Agarwal S, Antonini S, Costa TEIJB, Diclehan O, Fassnacht M, et al. Assessment of prognostic factors in pediatric adrenocortical tumors: the modified pediatric S-GRAS score in an international multicenter cohort-a work from the ENSAT-PACT working group. Eur J Endocrinol. [Internet]. 2024 [citado em 12 out 2024]; 191(1):64-74. DOI: https://doi.org/10.1093/ejendo/lvae079
15. Brondani VB, Fragoso MCBV. Pediatric adrenocortical tumor - review and management update. Curr Opin Endocrinol Diabetes Obes. [Internet]. 2020 [citado em 12 ago 2024]; 27(3):177-86. DOI: https://doi.org/10.1097/MED.0000000000000540
16. Riedmeier M, Antonini SRR, Brandalise S, Costa TEJB, Daiggi CM, Figueiredo BC, et al. International consensus on mitotane treatment in pediatric patients with adrenal cortical tumors: indications, therapy, and management of adverse effects. Eur J Endocrinol. [Internet]. 2024 [citado em 12 ago 2024]; 190(4):G15-G24. DOI: https://doi.org/10.1093/ejendo/lvae038
Downloads
Published
Issue
Section
License
Copyright (c) 2026 Revista Família, Ciclos de Vida e Saúde no Contexto Social
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Each of the authors of the manuscript must complete and sign a copy of Statement of Responsibility and Copyright Transfer Agreement, which must be attached, by the submitting author, in step 4 of the submission process in the journal system (Click on the "Browse" option, select the file that should be inserted in pdf format, click on the "Download" button, in the "Title" field type: Declaration of responsibilities, then click the "Save and Continue" button and proceed with the submission process.
Note: Including scanned signature will not be accepted. Each author of the manuscript must complete a declaration individually.
REFACS de Universidade Federal do Triângulo Mineiro está licenciado com uma Licença Creative Commons - Atribuição-NãoComercial 4.0 Internacional.
Baseado no trabalho disponível em www.uftm.edu.br.
Podem estar disponíveis autorizações adicionais às concedidas no âmbito desta licença em http://www.uftm.edu.br/refacs.
Revistas UFTM